Amycretin: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions have not been publicly disclosed. Clinical trial formulations are managed per protocol requirements.
Protocol Quick-Reference
Chronic weight management in adults with obesity or overweight
Dosing
Amount
1.25-60 mg (SC) or up to 100 mg (oral)
Frequency
Once weekly (SC) or once daily (oral)
Duration
Up to 36 weeks (Phase 1b/2a)
Administration
Route
SCSchedule
Once weekly (subcutaneous formulation)
Timing
Dose escalation required. SC formulation administered weekly; oral formulation with SNAC enhancer taken daily. Both formulations under investigation.
Cycle
Duration
Ongoing (long-term use expected)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk factors
CMP
When: 12 weeks
Why: Monitor metabolic parameters during treatment
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority
- โHigh GI adverse event rates in Phase 1b/2a: nausea 82%, vomiting 53%, diarrhea 41%
- โ33% overall discontinuation rate in Phase 1b/2a (majority unrelated to adverse events)
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Once weekly (subcutaneous) | Up to 36 weeks in Phase 1b/2a | No weight loss plateau at higher doses. Dose-dependent efficacy across cohorts. 125 participants at single center in San Antonio, TX. | ||
| Once daily (oral tablet with SNAC) | 12 weeks in Phase 1 | Oral formulation uses SNAC (same enhancer as oral semaglutide). 144 participants enrolled. | ||
| Once weekly (subcutaneous) | 36 weeks | 448 participants with T2D. Both SC and oral formulations evaluated. Phase 3 in T2D planned for 2026. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Not applicable - amycretin is provided as a ready-to-use subcutaneous injection or oral tablet
Recommended Injection Sites
- โAbdomen (subcutaneous formulation)
- โThigh (subcutaneous formulation)
- โUpper arm (subcutaneous formulation)
๐งStorage Requirements
Storage conditions have not been publicly disclosed. Clinical trial formulations are managed per protocol requirements.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Disclaimer#
Amycretin is an investigational drug not yet approved by any regulatory authority. All dosing information is derived from clinical trial protocols and published results. Amycretin should only be used within approved clinical trials.
Clinical Trial Dosing#
Subcutaneous Formulation (Phase 1b/2a, Obesity)#
The Phase 1b/2a trial evaluated once-weekly subcutaneous amycretin at multiple dose levels over up to 36 weeks in 125 participants with overweight or obesity:
| Dose | Duration | Weight Loss |
|---|---|---|
| 1.25 mg | 20 weeks | 9.7% |
| 5 mg | 28 weeks | 16.2% |
| 20 mg | 36 weeks | 22.0% |
| 60 mg | 36 weeks | 24.3% |
| Placebo | Various | 1.1-2.3% |
Oral Formulation (Phase 1, First-in-Human)#
Once-daily oral amycretin with SNAC over 12 weeks in 144 participants:
| Dose | Weight Loss (12 weeks) |
|---|---|
| 50 mg | 10.4% |
| 2 x 50 mg | 13.1% |
| Placebo | 1.2% |
Subcutaneous and Oral (Phase 2, Type 2 Diabetes)#
36 weeks in 448 patients with T2D on metformin:
- SC amycretin: Up to 14.5% weight loss, 1.8% HbA1c reduction
- Oral amycretin: Up to 10.1% weight loss, 1.5% HbA1c reduction
- No plateau at higher doses
Dose Escalation#
Like other GLP-1/amylin-based therapies, amycretin uses dose escalation to improve GI tolerability. Patients start at lower doses and gradually increase to the target maintenance dose. GI adverse events are most common during the escalation phase and tend to diminish at maintenance doses.
Administration#
Subcutaneous Injection#
- Once-weekly injection
- Standard subcutaneous injection sites (abdomen, thigh, upper arm)
- Rotate injection sites
Oral Tablet#
- Once-daily oral dosing
- Contains SNAC permeation enhancer (same as Rybelsus)
- Specific fasting requirements not fully disclosed
Dual Formulation Strategy#
Amycretin is being developed in parallel as both SC and oral formulations, similar to VK2735. This dual strategy provides patient choice:
| Feature | Subcutaneous | Oral |
|---|---|---|
| Frequency | Once weekly | Once daily |
| Route | SC injection | Oral tablet |
| Weight loss (obesity) | Up to 24.3% (36wk) | Up to 13.1% (12wk) |
| Weight loss (T2D) | Up to 14.5% (36wk) | Up to 10.1% (36wk) |
| Enhancement | N/A | SNAC permeation enhancer |
Phase 3 Plans#
Novo Nordisk plans Phase 3 trials in both obesity and T2D beginning in 2026. Phase 3 dosing will be informed by the dose-response data from Phase 1b/2a and Phase 2 trials.
Dosing Context#
Amycretin belongs to the Metabolic category of research peptides. Dosing protocols for Amycretin are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Amycretin:
undefined#
Dose: undefined
Frequency: Once weekly (subcutaneous)
Duration: Up to 36 weeks in Phase 1b/2a
No weight loss plateau at higher doses. Dose-dependent efficacy across cohorts. 125 participants at single center in San Antonio, TX.
undefined#
Dose: undefined
Frequency: Once daily (oral tablet with SNAC)
Duration: 12 weeks in Phase 1
Oral formulation uses SNAC (same enhancer as oral semaglutide). 144 participants enrolled.
undefined#
Dose: undefined
Frequency: Once weekly (subcutaneous)
Duration: 36 weeks
448 participants with T2D. Both SC and oral formulations evaluated. Phase 3 in T2D planned for 2026.
Reconstitution and Preparation#
Not applicable - amycretin is provided as a ready-to-use subcutaneous injection or oral tablet
Injection Sites#
Recommended injection sites for Amycretin include:
- Abdomen (subcutaneous formulation)
- Thigh (subcutaneous formulation)
- Upper arm (subcutaneous formulation)
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions have not been publicly disclosed. Clinical trial formulations are managed per protocol requirements.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Amycretin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.